Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 344 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Recurrent Malignant Brain Neoplasm Clear all

Conditions: Brain Cancer, Malignant Brain Tumor, Recurrent Brain Tumor, Progressive Malignant Brain Tumor, Brain Tumor, Pediatric, Brain Tumor Adult
Interventions: Magrolimab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 3 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: San Francisco, California • Salt Lake City, Utah

Conditions: Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 6 Years to 21 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more

Conditions: Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
Interventions: Ommaya Reservoir, Methotrexate, Leucovorin; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 22 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors
Interventions: chemotherapy, suramin; Drug
Lead sponsor: Emory University; Other
Eligibility: 15 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2004
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Gliosarcoma, Glioblastoma
Interventions: Vandetanib and Etoposide; Drug
Lead sponsor: Annick Desjardins; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors
Interventions: PET scan with 124I-cRGDY-PEG-dots; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions: filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, autologous bone marrow transplantation, bone marrow ablation with stem cell support; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 16 Years to 120 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: alvocidib, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Glioma, Brain Neoplasms
Interventions: DTI-015; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
Interventions: IV Zometa; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Brain and Central Nervous System Tumors
Interventions: Erlotinib + Sirolimus; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer
Interventions: trastuzumab, tipifarnib; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Fort Sam Houston, Texas • San Antonio, Texas

Conditions: Malignant Gliomas, CNS, Brain Cancer, Cancer
Interventions: Perifosine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors
Interventions: O6-benzylguanine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2009
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more

Conditions: Brain and Central Nervous System Tumors
Interventions: Ad5CMV-p53 gene, conventional surgery; Biological · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 8
States / cities: San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Conditions: Glioblastoma or Gliosarcoma
Interventions: Single intratumoral injection of DNX-2401, Interferon-gamma; Drug
Lead sponsor: DNAtrix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more

Conditions: Brain and Central Nervous System Tumors
Interventions: temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique; Drug · Genetic · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain Neoplasm, Recurrent Brain Neoplasm
Interventions: Cognitive Assessment, Computer-Assisted Cognitive Training, Psychosocial Assessment and Care, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Years to 16 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 27
States / cities: Aurora, Colorado • Wilmington, Delaware • Washington D.C., District of Columbia + 24 more

Conditions: Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
Interventions: Dordaviprone (ONC201); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 8
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Medulloblastoma
Interventions: Treatment with MTX110; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Year to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions: arsenic trioxide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 40 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
Interventions: Palbociclib, Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions: filgrastim, carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 35 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Medulloblastoma, Astrocytoma, Grade III, Glioblastoma, Anaplastic Astrocytoma, Brain Stem Neoplasms, Malignant, Oligodendroblastoma, Anaplastic Oligodendroglioma, Malignant Glioma
Interventions: Mebendazole; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 1 Year to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: St. Petersburg, Florida • Baltimore, Maryland

Search by objective public record fields.

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

Suramin in Treating Patients With Recurrent Primary Brain Tumors

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer

Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas

Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

O(6)-Benzylguanine in Treating Patients With Malignant Glioma

Gene Therapy in Treating Patients With Recurrent Malignant Gliomas

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy

ONC201 in Pediatric H3 K27M Gliomas

Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors